CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials

The Maternal Embryonic Leucine Zipper Kinase (MELK) has been reported to be a genetic dependency in several Cancer types. MELK RNAi and small-molecule inhibitors of MELK block the proliferation of various Cancer cell lines, and MELK knockdown has been described as particularly effective against the highly-aggressive basal/triple-negative subtype of breast Cancer. Based on these preclinical results, the MELK Inhibitor OTS167 is currently being tested as a novel chemotherapy agent in several clinical trials. Here, we report that mutagenizing MELK with CRISPR/Cas9 has no effect on the fitness of basal breast Cancer cell lines or cell lines from six other Cancer types. Cells that harbor null mutations in MELK exhibit wild-type doubling times, cytokinesis, and anchorage-independent growth. Furthermore, MELK-knockout lines remain sensitive to OTS167, suggesting that this drug blocks cell division through an off-target mechanism. In total, our results undermine the rationale for a series of current clinical trials and provide an experimental approach for the use of CRISPR/Cas9 in preclinical target validation that can be broadly applied.